Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data

Hematol Oncol. 2019 Oct;37(4):490-492. doi: 10.1002/hon.2645. Epub 2019 Jul 24.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Allografts
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Brentuximab Vedotin
  • Disease-Free Survival
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / mortality*
  • Hodgkin Disease / therapy*
  • Humans
  • Immunoconjugates / administration & dosage
  • Male
  • Middle Aged
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Retrospective Studies
  • Survival Rate

Substances

  • Antineoplastic Agents, Immunological
  • Immunoconjugates
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Brentuximab Vedotin